← All thesesACMRNeutralMedium convictionTuesday 17 November 2026עברית

ACM Research

This is the archived full research. Read the story

Makes the machines that wash and copper-plate silicon wafers between the steps of making a chip, and sells almost all of them to factories in mainland China.

Our viewNeutral Medium conviction
The scores
The profile · 1-4
Growth3/4 ↑

Guidance now 38%-42% for FY2026 and Q3 revenue grew 37%; cleaning grew again after falling 14% in Q2.

Business quality3/4 →

An 87% repeat-order rate signals a real qualification-based switching cost, but a named local China entrant is a live, growing threat.

Financial position2/4 ↓

The plan needs outside money already raised once (May 2026) and being raised again via the Hong Kong listing, while operations burn cash.

Execution record3/4 →

Beat consensus EPS in 6 of the last 8 quarters and raised guidance twice this year, but PECVD and Track slipped to year-end again.

Per share capture2/4 ↓

A shrinking 74.6% subsidiary stake and a below-market equity raise both dilute ACM Research's per-share economic claim.

Potential3/4 ↑

A credible $4 billion long-term target rests on PECVD, Track and panel-level plating, which are still mostly pre-production.

Risk profile2/4 →

Historic revenue is overwhelmingly China-sourced, and both operating subsidiaries now sit on the U.S. Entity List.

Valuation3/4 ↓

About 19.5 times operating profit, 87% of a three-stage value near $50.85 at an 8% return: fair, inside the 20% margin.

Evidence quality3/4 →

Filings, transcript and FINRA data cross-check cleanly with no vendor/filing gaps, but the $4 billion target and SAM rest on management-selected third-party data.

The bet · 2-3 years
Asymmetric2.1×

If it works 2.1× · if it fails you keep about 100%.

The Verdict

We rate ACM Research Neutral. It builds machines that clean and plate silicon wafers, but nearly all its sales go to mainland China, its operating arms sit on a US trade blacklist and its profit has not turned into cash, so the business is mixed. The price is a little under our value and cheaper than both listed rivals, but not by the cushion those risks call for. As a bet it is asymmetric: the new tool lines could add a lot if they win, and little is lost if they never sell. A production order for those tools and cash matching the profit would make it Attractive.

The long caseChina wants its chip plants to buy home-made tools, and deposition and coating are big markets; if ACM's new tools pass customer trials, buyers who already trust it can order.

How we weighed it

The price against our value

Cuts both ways

Price at 87% of our value

The price is a little under our value once the outside owners of its Chinese arm are counted, inside the margin of safety.

The business

Cuts both ways

Mixed

Machines that clean and plate wafers, but profit has not turned into cash.

Growth against what the price assumes

Cuts both ways

Growth depends on new tool lines winning production orders, none yet.

What could go wrong

Against it

Both operating arms are blacklisted, sales sit in one country forecast to shrink, and a few customers dominate.

Against competitors

In its favour

Cheaper than both listed rivals its own filing names, on every measure.

How its group is behaving

Cuts both ways

Chip-equipment names move together on spending news; its China exposure is its own.

The latest news and report

Against it

The cleaning rebound came, but no new-tool order is filed and the quarter used cash again.

The evidence under this - 9 claims
C18facthigh confidence
ACM has delivered more than 1,435 tools since 2009, of which more than 1,255 (about 87%) were repeat orders or reorders, and shipped its 2,000th electroplating chamber in Q2 2026 (versus the 500th in 2022 and the 1,500th in 2025).
current state · 2026-08-07written 2026-08-31
C03facthigh confidence
Q2 2026 revenue was $292.9 million, up 36.0% year over year; FY2026 revenue guidance was raised to $1.125-1.175 billion in August and to $1.24-1.28 billion (38%-42% growth) on 5 November, which implies Q4 revenue of $348M to $388M.
  1. 2026-10-23editedACM's own notice of 19 October sets the third-quarter results for 5 November, not the 4 November a vendor estimated; the refresh date moves with it
  2. 2026-11-05editedQ3 release raised the 2026 revenue guide a second time
forwardwritten 2026-08-31
C25facthigh confidence
Against the two listed, filing-confirmed competitors (Lam Research, Applied Materials), ACM trades at a discount on every cohort multiple at the 4 November 2026 close - EV/EBIT 12.9x vs a 29.75x median, EV/Sales 1.9x vs 10.0x, P/E 26.0x vs 32.25x - while its TTM revenue growth (29.1%) is the second highest of the three, behind Lam's 33.4%, and its operating margin (14.5%) and ROIC (5.3%) are the lowest.
  1. 2026-10-23editedre-struck at the 22 October close from 31 August: ACM's EV/EBIT 29.1x to 19.1x against a peer median of 42.1x to 30.65x; Lam's refreshed growth (33.4%) now exceeds ACM's 27.3%, so ACM is second fastest, not fastest
  2. 2026-11-05editedre-struck at the 4 November close from a new pack; the sentence on the group re-rating since 31 August dropped because the refreshed cohort carries no comparable history
current state · 2026-11-04written 2026-08-31
C11facthigh confidence
Substantially all of ACM's historical semiconductor-equipment sales have been to customers in mainland China; the company is expanding direct sales in North America, Europe and Southeast Asia.
current state · 2026-03-02written 2026-08-31
C20factmedium confidence
ACM's own 10-K cites Gartner estimating global WFE grew to $138.5 billion in 2026 (up 11.8%) while mainland-China WFE is estimated to decline 9.9%, from $39.3 billion in 2025 to $35.4 billion in 2026.
forwardwritten 2026-08-31
C23facthigh confidence
As of the Q3 2026 release on 5 November, ACM's PECVD and Track platforms are not reported as separate product lines and neither the release nor the Q3 10-Q, filed 6 November, names a production order for either; as of the Q2 2026 call both were in customer evaluation with production qualification anticipated by year-end 2026. On the Q3 call the chief executive said the Track system has started customer pre-production alongside a scanner and PECVD is making progress, but no production order was named.
against this

A related new platform, horizontal panel-level plating, already booked its first production order in Q2 2026 (C35), which management points to as evidence the evaluation-to-production path is real rather than a standing promise.

  1. 2026-10-23editedACM's own notice of 19 October sets the third-quarter results for 5 November, not the 4 November a vendor estimated; the refresh date moves with it
  2. 2026-11-05editedQ3 release names no PECVD or Track production order
  3. 2026-11-05editedQ3 call read: Track is in customer pre-production, PECVD progressing, still no production order named.
  4. 2026-11-10editedthe Q3 2026 10-Q, filed 6 November, was read and names no PECVD or Track production order
current state · 2026-11-06written 2026-08-31
C40estimatemedium confidence
At the 4 November 2026 close, ACM's 12.9x EV/EBIT, down from 29.1x on 31 August and 19.1x on 22 October and 43% of the two-peer median of 29.75x, prices continued growth with less to spare: the discount to Lam Research and Applied Materials is wider than it was. C24 (ACM's own valuation history), C25 (the two-peer filed-cohort discount) and C03 (FY2026 guidance of 38%-42% growth) read together against the EV/EBIT frame.
derivedC24 (ACM's own valuation history), C25 (the two-peer filed-cohort discount) and C03 (FY2026 guidance of 25%-30% growth) read together against the EV/EBIT frame.
against this

A skeptic could read the same discount as the market correctly pricing structurally lower returns on capital (ROIC 4.4% vs a 23.5%-40.8% peer range, C25) rather than as a temporary gap that closes as growth continues.

  1. 2026-10-23editedre-struck at the 22 October close: 29.1x EV/EBIT to 19.1x, with the cohort median 42.1x to 30.65x; the reading moves from 'a narrowing discount' to a wider one, with the business evidence unchanged
  2. 2026-11-05editedre-struck at the 4 November close
current state · 2026-11-04written 2026-08-31
C24facthigh confidence
At the 4 November 2026 close of $44.43 ACM trades at a TTM P/E of 25.98x and EV/EBITDA of 8.01x, against prior-six-fiscal-year medians of 20.99x and 10.83x: the P/E is about 24% above its own median and the EV/EBITDA 26% below it. TTM ROIC is 5.3% versus a prior median of 6.3%.
  1. 2026-10-23editedre-struck at the 22 October close (49.12) from the 31 August close (72.82): P/E 32.25x to 22.47x and EV/EBITDA 14.83x to 9.92x, so ACM no longer trades above both of its own medians
  2. 2026-11-05editedre-struck at the 4 November close from a new pack
current state · 2026-11-04written 2026-08-31
C21management claimmedium confidence
ACM estimates, from third-party reports and customer data, that its current products address about $7.3B of wafer cleaning, $5.3B of PECVD, $3.0B of Track, $2.6B of furnace and $1.5B of ECP within the global WFE market.
against this

The by-product-line SAM figures are described as based on 'third-party reports and customer information' without naming which third parties beyond the general Frost & Sullivan citation used elsewhere, so the individual product-line splits cannot be independently checked against a named external source.

current state · 2026-03-02written 2026-08-31
01

The company

A chip is built up in hundreds of steps, and between many of them the silicon wafer must be washed free of specks far too small to see. ACM Research makes machines that do that washing one wafer at a time, replacing older tools that dip whole batches into a bath.

Cleaning was about 70% of 2025 sales. The rest is copper-plating machines, furnaces, packaging equipment and two newer lines called PECVD and Track.

The evidence under this - 2 claims
C01facthigh confidence
ACM Research designs and sells single-wafer wet-cleaning tools plus ECP plating, furnace, PECVD, Track and advanced-packaging equipment for chip fabs.
current state · 2026-03-02written 2026-08-31
C04facthigh confidence
FY2025 revenue mix was about 69.5% single-wafer cleaning/Tahoe/semi-critical cleaning, 22.1% ECP/furnace/other, and 8.4% advanced packaging (ex-ECP) plus services and spares.
historical · FY2025written 2026-08-31

How it makes money

A chip factory first tests a tool on its own line, then buys it outright, and spare parts and service follow. The next sale comes when that factory adds capacity, or a sister factory copies a line that already works.

The evidence under this - 2 claims
C04facthigh confidence
FY2025 revenue mix was about 69.5% single-wafer cleaning/Tahoe/semi-critical cleaning, 22.1% ECP/furnace/other, and 8.4% advanced packaging (ex-ECP) plus services and spares.
historical · FY2025written 2026-08-31
C18facthigh confidence
ACM has delivered more than 1,435 tools since 2009, of which more than 1,255 (about 87%) were repeat orders or reorders, and shipped its 2,000th electroplating chamber in Q2 2026 (versus the 500th in 2022 and the 1,500th in 2025).
current state · 2026-08-07written 2026-08-31
Where the money comes from, stream by stream
StreamShare of sales (FY2025)How it earns it
Single-wafer cleaning, Tahoe and semi-critical cleaning69.5%Wet-cleaning tools sold to chip fabs, mostly in mainland China, that strip particles and residue between process steps.
ECP (front-end and packaging), furnace and other technologies22.1%Copper-plating tools for chip wiring and packaging, plus furnaces and newer deposition tools, sold per system.
Advanced packaging (excluding ECP), services and spares8.4%Wet tools for chip packaging lines, plus spare parts and service on the installed base.

Who runs it

David Wang founded ACM Research in 1998 and still runs it; the same finance chief has served since 2019, and the CEO's brother runs the Chinese subsidiary. Through shares with twenty votes each, Wang alone controls most of the vote, so outside holders cannot outvote him. Bonuses have no formula: the board decides, citing sales growth and margins. Long-term pay is stock options, which pay only if the share price rises.

The evidence under this - 3 claims
C53facthigh confidence
David H. Wang founded ACM Research in 1998 and has been chief executive, president and a director since, holding more than 100 patents; Mark McKechnie has been chief financial officer since November 2019; Jian Wang, the CEO's brother, has run ACM Shanghai since November 2019 and Lisa Feng has been its CFO since then.
current state · 2026-04-13written 2026-10-04
C51facthigh confidence
As of April 13, 2026 the ten directors and executive officers as a group beneficially owned 18.8% of Class A on an as-converted basis (including 3.79 million option shares) and 92.5% of Class B, for 64.5% of the vote; founder David Wang held 14.4% of Class A as converted, 83.5% of Class B and 57.2% of the vote; BlackRock, at 12.1%, was the largest outside holder.
current state · 2026-04-13written 2026-10-04
C52facthigh confidence
ACM Research has no established bonus policy: the compensation committee pays annual cash bonuses at its sole discretion with no weights, thresholds or targets, citing for 2025 revenue growth, improved operating margins, new products and customers; long-term pay is stock options in ACM Research and ACM Shanghai, granted irregularly, and no named executive received options in 2025.
against this

The CD&A credits 'improved operating margins' for 2025, while the filed operating margin fell from 19.3% in FY2024 to 12.1% in FY2025 (S01); the proxy does not say which margin it meant, which is what a pay plan with no stated measure allows.

current state · 2026-04-27written 2026-10-04
02

Why it wins, and who could beat it

Why customers come back

A chip factory spends months approving a tool against its own recipe. Once a tool passes, the next order goes to the same machine, because a rival's would have to pass all over again.

The trace is in the orders: more than 1,255 of the 1,435-plus tools shipped since 2009 were repeats, and the plating line went from its 500th chamber in 2022 to its 2,000th this year. Lam Research, the largest rival, credits its own installed base with the same pull in its annual report.

The evidence under this - 2 claims
C18facthigh confidence
ACM has delivered more than 1,435 tools since 2009, of which more than 1,255 (about 87%) were repeat orders or reorders, and shipped its 2,000th electroplating chamber in Q2 2026 (versus the 500th in 2022 and the 1,500th in 2025).
current state · 2026-08-07written 2026-08-31
C17facthigh confidence
Lam Research's own FY2026 10-K names 'deposition, etch, and clean' as its three core process markets and cites 'cycles of learning from our broad installed base' as a competitive advantage - independently confirming clean is a real Lam business and that installed-base/repeat-order dynamics are a recognized mechanism in this industry.
current state · 2026-08-07written 2026-08-31

The threat

NAURA, a Chinese toolmaker, sells cleaning, plating and furnace machines to the same mainland factories, and ACM's own annual report warns of more local entrants. NAURA grew strongly in 2025 on China's push to buy home-grown tools, though a trade paper saw thinner margins ahead.

The evidence under this - 3 claims
C16facthigh confidence
ACM's 10-K names Lam Research, NAURA, SCREEN Holdings, SEMES, Tokyo Electron and Kokusai as principal cleaning/plating/furnace competitors, and Lam Research, Applied Materials and Suzhou Jingtuo for PECVD and Track.
current state · 2026-03-02written 2026-08-31
C31facthigh confidence
ACM's 10-K names 'new and emerging companies, including new competitors from mainland China' and 'additional competitors based in mainland China across multiple product lines due in part to the recent entrants of local equipment suppliers' as a competitive risk, and separately names NAURA specifically as a principal China-based rival.
current state · 2026-03-02written 2026-08-31
C39factmedium confidence
DigiTimes, reporting independently on NAURA's own results, described NAURA delivering 'strong 2025 revenue growth on rising chip tool demand and domestic substitution,' with 'weaker margins and intensifying competition' signaling a tougher next phase.
current state · 2026-04-20written 2026-08-31

The rivals: LRCX, AMAT, and 1 more that is private, in-house or listed abroad.

Who else does this, rival by rival
TickerRivalWhere it competesHow far alongPriced against it
NAURA Technology GroupPriced against it: Listed abroadCleaning, ECP plating, furnace and advanced-packaging toolsOn saleListed abroad
LRCX · AMATLam Research, Applied Materials and Suzhou JingtuoPriced against it: YesPECVD and Track platformsOn saleYes
03

How big it could get

How big this could get

The world's chip factories will spend about $138.5B on equipment in 2026. ACM reckons its current machines can bid for $7.3B of cleaning, $5.3B of PECVD, $3.0B of Track, $2.6B of furnaces and $1.5B of plating. It sold $901.3M last year.

The catch is where. Mainland China's equipment spending is forecast to fall 9.9% in 2026, from $39.3B to $35.4B.

The evidence under this - 4 claims
C20factmedium confidence
ACM's own 10-K cites Gartner estimating global WFE grew to $138.5 billion in 2026 (up 11.8%) while mainland-China WFE is estimated to decline 9.9%, from $39.3 billion in 2025 to $35.4 billion in 2026.
forwardwritten 2026-08-31
C21management claimmedium confidence
ACM estimates, from third-party reports and customer data, that its current products address about $7.3B of wafer cleaning, $5.3B of PECVD, $3.0B of Track, $2.6B of furnace and $1.5B of ECP within the global WFE market.
against this

The by-product-line SAM figures are described as based on 'third-party reports and customer information' without naming which third parties beyond the general Frost & Sullivan citation used elsewhere, so the individual product-line splits cannot be independently checked against a named external source.

current state · 2026-03-02written 2026-08-31
C02facthigh confidence
FY2025 revenue was $901.3 million, up 15.2%, a sharp deceleration from 40.2% growth in FY2024 and 43.4% in FY2023.
historical · FY2025written 2026-08-31
C19factmedium confidence
SEMI, the semiconductor-equipment industry trade association, forecasts global wafer-fab-equipment sales growing 9.0% in 2026 and 7.3% in 2027, while separately expecting mainland-China equipment spending to 'gradually decline from 2026' even as China keeps the largest share of global spending.
forwardwritten 2026-08-31

Who has signed

Very little. Last quarter brought the first disclosed orders for a tool that plates large square panels instead of round wafers: one production order and one trial machine, both from unnamed customers and neither with a value.

The evidence under this - 1 claim
C35facthigh confidence
In Q2 2026 ACM received a production order for its horizontal panel-level plating tool from an existing mainland-China customer, plus an evaluation-system order for a 310x310mm tool from a new customer in Asia, scheduled for Q4 2026 delivery - the company's first disclosed panel-level plating orders.
historical · Q2 2026written 2026-08-31
Where the growth is coming from, business by business

Where the growth is coming from

BusinessShare of revenueGrowth: last quarterLast half-yearLast year
Total Single Wafer and Semi-Critical Cleaning Equipment57%+16.1%+2.1%+0.8%
ECP Front End And Packaging Furnace And Other Technologies30%+82.9%+120.7%+106.4%
Advanced Packaging (exclude ECP), Services & Spares13%+71.2%+96.6%+72.5%
Whole company100%+36.6%+36.3%+29.1%

The filed split through 2026-09-30. These rates are not carried forward: the reading below says why.

How we read it: The blend. The fast line is plating, an established product, not PECVD or Track, still in evaluation; its 181% rides a weak 2025 base and China capacity spending SEMI expects to fade.

04

The results

The numbers

Is it growing?Fast

Sales grew 29% over the twelve months to Sep 2026, faster than the 15% in the year to Dec 2025.

Dec 2021: $260MDec 2022: $389MDec 2023: $558MDec 2024: $782MDec 2025: $901M12 mo to Sep 2026: $1.14B$260M$1.14B
Is it profitable?Healthy

Operating margin is 14%, down from 17% in the year to Dec 2023.

Dec 2021: 15%Dec 2022: 15%Dec 2023: 17%Dec 2024: 19%Dec 2025: 12%12 mo to Sep 2026: 14%15%14%
Does growth pay off?Flat

Running costs take 29¢ of each sales dollar, about where it was (29¢) in the year to Dec 2021.

Dec 2021: 29¢Dec 2022: 32¢Dec 2023: 32¢Dec 2024: 31¢Dec 2025: 32¢12 mo to Sep 2026: 29¢29¢29¢
Does it earn good returns?Low

Each dollar put into the business earns 7.2% a year after tax, about where it was (8.6%) in the year to Dec 2021.

Dec 2021: 8.6%Dec 2022: 6.1%Dec 2023: 9.9%Dec 2024: 12%Dec 2025: 6.9%12 mo to Sep 2026: 7.2%8.6%7.2%
How long can it keep going?Long runway

It used $199M of cash over the last twelve months, so the $952M it holds lasts about 4.8 years at that pace.

Dec 2021: −$49.2MDec 2022: −$153MDec 2023: −$137MDec 2024: $70.0MDec 2025: −$66.6M12 mo to Sep 2026: −$199M−$49.2M−$199M
Is the balance sheet safe?Net cash

It holds $952M of cash against $343M of debt, $609M more cash than it owes.

Dec 2021: $557MDec 2022: $191MDec 2023: $111MDec 2024: $244MDec 2025: $505M12 mo to Sep 2026: $609M$557M$609M
Are shares being diluted?Creeping

The share count rose 13% in 4.8 years, and pay in shares costs 2.6% of sales.

Dec 2021: 65.4MDec 2022: 65.3MDec 2023: 64.9MDec 2024: 66.2MDec 2025: 67.3M12 mo to Sep 2026: 73.6M65.4M73.6M
All the numbers

Filed figures from the company's 10-K and 10-Q, read 2026-11-09. Fiscal years end in December.

Dec 2021Dec 2022Dec 2023Dec 2024Dec 202512 mo to Sep 2026
Size and growth
Sales$260M$389M$558M$782M$901M$1.14B
Sales growth+66%+50%+43%+40%+15%+29%
Profit
Gross margin44%47%50%50%44%43%
Operating margin15%15%17%19%12%14%
Net margin15%10%14%13%10%10%
What growth costs, per sales dollar
Research and development13%16%17%13%16%15%
Sales and marketing10%10%8.4%8.4%8.5%7.7%
General and admin5.9%5.8%7.3%8.9%7.6%6.0%
Pay in shares2.0%2.0%4.9%6.3%3.7%2.6%
Capital spending3.5%23%11%11%6.2%11%
Cash
Cash from operations−$40.1M−$62.2M−$75.3M$152M−$10.3M−$72.4M
Free cash flow−$49.2M−$153M−$137M$70.0M−$66.6M−$199M
Balance sheet
Cash and short-term investments$592M$268M$203M$427M$793M$952M
Debt$35.0M$77.0M$92.1M$183M$288M$343M
Net cash$557M$191M$111M$244M$505M$609M
Returns and shares
Return on capital8.6%6.1%9.9%12%6.9%7.2%
Shares (diluted)65.4M65.3M64.9M66.2M67.3M73.6M

What growth costs

Growing has not made ACM Research cheaper to run. Its spending on research, selling and administration has stayed about the same share of every sales dollar while sales more than tripled, and management plans to keep it there. Profit margins have risen and fallen with the price it gets for its tools, not with its size.

The evidence under this - 2 claims
C55facthigh confidence
Per sales dollar, R&D rose from 13.2 cents in FY2021 to 16.1 in FY2025 (17.0 before China government grants), sales and marketing fell from 10.3 to 8.5, admin rose from 5.9 to 7.6 and stock pay from 2.0 to 3.7; total operating expense went from 29.3 cents to 32.2, and 30.5 in the year to June 2026, while revenue rose 3.5 times.
against this

Operating margin did widen from 14.9% in FY2021 to 19.3% in FY2024 before falling to 12.1% in FY2025, but the move tracked gross margin (44.2%, 50.1%, 44.4%), not operating cost; and FY2025 R&D includes $26.7 million of components for development tools (S01), lumpy rather than structural.

historical · FY2021 to the four quarters to June 2026written 2026-10-04
C29management claimmedium confidence
CFO Mark McKechnie said there is 'no change' to the 42%-48% gross-margin target despite tight, rising-cost component supply, citing pre-built raw-material inventory; R&D (16%-18%), G&A (5%-6%) and S&M (about 8%) opex ratios were also reaffirmed.
against this

Management's 'no change' framing came the same quarter the BIS Entity List restriction was already in effect and component costs were described as rising; the reaffirmed range has not yet been tested through a full quarter of the local-supplier substitution management described.

  1. 2026-10-23editedACM's own notice of 19 October sets the third-quarter results for 5 November, not the 4 November a vendor estimated; the refresh date moves with it
forwardwritten 2026-08-31

The last report (5 Nov)

Quarter ended September 2026, filed figures.

37%
Sales growth
against the same quarter a year earlier
25.5%
Growth from the quarter before
against 26.7% the quarter before that
15¢
Operating profit
per dollar of sales

The September quarter was strong. Sales rose 36.6% to $367.7M, the flagship cleaning line grew 16% after shrinking 14% in the June quarter, and the full-year forecast rose to $1.24B-$1.28B from $1.125B-$1.175B. Operating profit was 15.1% of sales against 10.7%.

Three things did not follow. Orders shipped grew 31%, slower than sales; the share of sales left after making the tools slipped to 41.5%; and cash fell to $1.28B from $1.36B. On the call, management said Track tools are in customer trials and shipments should rise in the fourth quarter, but named no first order for PECVD or Track.

What it did to the thesisThe cleaning rebound we were waiting for came. The first order for the new tool lines and the cash from operations are still missing, so the view stays Neutral.

The quarter in detail

Sales growth from the previous quarter, filed figures.

Earnings per share $0.55 against $0.51 expected.

The evidence under this - 6 claims
C57facthigh confidence
Q3 2026 revenue rose 36.6% to $367.687M; gross margin was 41.5% against 42.0%, below ACM's 42% to 48% target range; operating income was $55.5M, 15.1% of revenue, against 10.7%; GAAP net income per diluted share was $0.02 against $0.52, after a $39.1M unrealized loss on investments held by ACM Shanghai, and non-GAAP was $0.55 against $0.41. Shipments were $343.5M, up 30.6%, slower than revenue.
historical · Q3 2026written 2026-11-05
C58facthigh confidence
Q3 2026 revenue from single-wafer cleaning, Tahoe and semi-critical cleaning equipment was $210.721M, up 16.1% from $181.570M and about 58% from Q2's roughly $133M; ECP, furnace and other technologies rose 83% to $109.469M and advanced packaging (excluding ECP), services and spares rose 71% to $47.497M.
historical · Q3 2026written 2026-11-05
C03facthigh confidence
Q2 2026 revenue was $292.9 million, up 36.0% year over year; FY2026 revenue guidance was raised to $1.125-1.175 billion in August and to $1.24-1.28 billion (38%-42% growth) on 5 November, which implies Q4 revenue of $348M to $388M.
  1. 2026-10-23editedACM's own notice of 19 October sets the third-quarter results for 5 November, not the 4 November a vendor estimated; the refresh date moves with it
  2. 2026-11-05editedQ3 release raised the 2026 revenue guide a second time
forwardwritten 2026-08-31
C13management claimmedium confidence
Management said first-half 2026 order intake grew 105% year over year on a large backlog, and that shipments are expected to outgrow revenue in 2026 across every product category; Q3 shipments of $343.5M rose 30.6%, slower than the 36.6% rise in revenue. On the Q3 call the chief financial officer said Q4 shipments should be higher still, helped by the second Lingang building.
against this

Order intake is not independently verifiable and is a figure management chooses to disclose selectively. ACM Shanghai's own backlog figure is now published (C43) and is up 88.2% on a year earlier, which points the same way, but it is a mix of shipped-not-yet-recognised and future-shipment orders on Chinese accounting, so it does not confirm the 105% order-intake figure itself.

  1. 2026-10-01editedThe backlog disclosure this claim said was pending was published on 2026-09-30; the counter-evidence now points to it (C43) instead of saying it was awaited.
  2. 2026-10-23editedACM's own notice of 19 October sets the third-quarter results for 5 November, not the 4 November a vendor estimated; the refresh date moves with it
  3. 2026-11-05editedQ3 shipments grew slower than revenue
  4. 2026-11-05editedQ3 call read: the chief financial officer says Q4 shipments should be higher than Q3.
forward · 2026-11-05written 2026-08-31
C23facthigh confidence
As of the Q3 2026 release on 5 November, ACM's PECVD and Track platforms are not reported as separate product lines and neither the release nor the Q3 10-Q, filed 6 November, names a production order for either; as of the Q2 2026 call both were in customer evaluation with production qualification anticipated by year-end 2026. On the Q3 call the chief executive said the Track system has started customer pre-production alongside a scanner and PECVD is making progress, but no production order was named.
against this

A related new platform, horizontal panel-level plating, already booked its first production order in Q2 2026 (C35), which management points to as evidence the evaluation-to-production path is real rather than a standing promise.

  1. 2026-10-23editedACM's own notice of 19 October sets the third-quarter results for 5 November, not the 4 November a vendor estimated; the refresh date moves with it
  2. 2026-11-05editedQ3 release names no PECVD or Track production order
  3. 2026-11-05editedQ3 call read: Track is in customer pre-production, PECVD progressing, still no production order named.
  4. 2026-11-10editedthe Q3 2026 10-Q, filed 6 November, was read and names no PECVD or Track production order
current state · 2026-11-06written 2026-08-31
C34facthigh confidence
At the end of Q3 2026 ACM held gross cash (plus restricted cash and short-term deposits) of $1.28 billion and net cash of about $0.9 billion, against about $343M of borrowings, down from $1.36 billion and $1.0 billion at June 30; accounts receivable were $704.7M and inventories $851.2M.
  1. 2026-10-23editedACM's own notice of 19 October sets the third-quarter results for 5 November, not the 4 November a vendor estimated; the refresh date moves with it
  2. 2026-11-05editedQ3 balance sheet cash and borrowings
current state · 2026-09-30written 2026-08-31
What management did with the money

It has been raising money, not returning it. In May it sold 2.9 million new shares at $52.00 for $149.85M, and in February it sold part of its stake in the Chinese subsidiary for about $111M. That subsidiary also raises its own outside money, which with its employees' option exercises shrank ACM Research's share of it to 72.8% by September.

Insiders in 2026Q3: 10 purchases and 20 sales, from their Form 4 filings.

The evidence under this - 4 claims
C15facthigh confidence
In a May 2026 registered direct offering, ACM Research sold 2,884,615 Class A shares at $52.00 to institutional investors managed by Tekne Capital, raising about $149.85 million in net proceeds.
historical · 2026-05-12written 2026-08-31
C38facthigh confidence
On February 6, 2026, ACM Research sold approximately 1.3% of its own shares held in ACM Shanghai for gross proceeds of about $111 million, part of the $845 million net cash position reported for year-end 2025.
historical · 2026-02-06written 2026-08-31
C08facthigh confidence
ACM Research holds a direct 72.8% ownership interest in ACM Shanghai, its principal operating subsidiary listed on Shanghai's STAR Market (688082), down from 74.6% at 31 December 2025 and 73.2% at 30 June 2026: ACM sold ACM Shanghai shares for $110.2M gross in the nine months, and ACM Shanghai employees' option exercises diluted it further; the September 2025 private offering had raised about $623 million.
against this

74.6% is still a clear controlling, consolidating majority stake, and ACM Shanghai paid a $36.8 million dividend up to ACM Research and minority holders in the same September 2025 window (C33), so capital has flowed back as well as out.

  1. 2026-11-10editedthe Q3 2026 10-Q, filed 6 November, was read: the stake is 72.8% at 30 September, down from 74.6% at the year end
current state · 2026-09-30written 2026-08-31
C32inferencemedium confidence
Because ACM Shanghai has repeatedly raised its own outside capital (the September 2025 private offering cut ACM Research's stake to 74.6%), further ACM Shanghai capital raises would keep diluting ACM Research shareholders' claim on ACM Shanghai's earnings even as consolidated revenue keeps growing.
derivedC08 (ownership fell after the September 2025 raise) combined with the pattern of ACM Shanghai independently accessing China's capital markets through its own STAR listing and a follow-on private placement, while ACM Research separately raised its own equity in May 2026 (C15) - a subsidiary with its own listing and its own capital-raising history is structurally likely to raise again as it funds Lingang and other expansion.
against this

ACM Shanghai also paid a $36.8 million dividend up to ACM Research and NCI holders in September 2025 (C33), so capital has flowed back as well as out, and 74.6% remains a clear majority stake with consolidation and control intact.

forwardwritten 2026-08-31
05

The price, and where we disagree

In short. Fair. The price is about 87% of what we think the business is worth, at an 8% yearly return, once the outside owners of its Chinese arm are counted.

Share price
$49.88
close,
Company value for each $1 of operating profit
12.9
rivals' middle 29.8

The company has raised its full-year forecast three times this year, most recently on 5 November, and says first-half orders more than doubled. The September-quarter release showed cleaning growing again; the first production order for PECVD or Track, both still on trial, was not in it or on the call.

The quarterly filing, due in days, should say what cash from operations was. The next full report is expected on 25 February 2027.

The evidence under this - 4 claims
C03facthigh confidence
Q2 2026 revenue was $292.9 million, up 36.0% year over year; FY2026 revenue guidance was raised to $1.125-1.175 billion in August and to $1.24-1.28 billion (38%-42% growth) on 5 November, which implies Q4 revenue of $348M to $388M.
  1. 2026-10-23editedACM's own notice of 19 October sets the third-quarter results for 5 November, not the 4 November a vendor estimated; the refresh date moves with it
  2. 2026-11-05editedQ3 release raised the 2026 revenue guide a second time
forwardwritten 2026-08-31
C13management claimmedium confidence
Management said first-half 2026 order intake grew 105% year over year on a large backlog, and that shipments are expected to outgrow revenue in 2026 across every product category; Q3 shipments of $343.5M rose 30.6%, slower than the 36.6% rise in revenue. On the Q3 call the chief financial officer said Q4 shipments should be higher still, helped by the second Lingang building.
against this

Order intake is not independently verifiable and is a figure management chooses to disclose selectively. ACM Shanghai's own backlog figure is now published (C43) and is up 88.2% on a year earlier, which points the same way, but it is a mix of shipped-not-yet-recognised and future-shipment orders on Chinese accounting, so it does not confirm the 105% order-intake figure itself.

  1. 2026-10-01editedThe backlog disclosure this claim said was pending was published on 2026-09-30; the counter-evidence now points to it (C43) instead of saying it was awaited.
  2. 2026-10-23editedACM's own notice of 19 October sets the third-quarter results for 5 November, not the 4 November a vendor estimated; the refresh date moves with it
  3. 2026-11-05editedQ3 shipments grew slower than revenue
  4. 2026-11-05editedQ3 call read: the chief financial officer says Q4 shipments should be higher than Q3.
forward · 2026-11-05written 2026-08-31
C05facthigh confidence
In Q2 2026, cleaning revenue fell 14% year over year to $133 million (45% of revenue), while ECP/furnace/other grew 168% and advanced packaging (ex-ECP) grew 153%.
against this

Management said the cleaning decline reflects a product-cycle transition, not lost share: SPM (about a third of the cleaning market by ACM's own estimate) had 'very little revenue today' but a handful of tools shipped in H1 2026 with more than 20 guided for H2, so the segment total is depressed by a new-product ramp rather than only by losses at existing accounts.

historical · Q2 2026written 2026-08-31
C23facthigh confidence
As of the Q3 2026 release on 5 November, ACM's PECVD and Track platforms are not reported as separate product lines and neither the release nor the Q3 10-Q, filed 6 November, names a production order for either; as of the Q2 2026 call both were in customer evaluation with production qualification anticipated by year-end 2026. On the Q3 call the chief executive said the Track system has started customer pre-production alongside a scanner and PECVD is making progress, but no production order was named.
against this

A related new platform, horizontal panel-level plating, already booked its first production order in Q2 2026 (C35), which management points to as evidence the evaluation-to-production path is real rather than a standing promise.

  1. 2026-10-23editedACM's own notice of 19 October sets the third-quarter results for 5 November, not the 4 November a vendor estimated; the refresh date moves with it
  2. 2026-11-05editedQ3 release names no PECVD or Track production order
  3. 2026-11-05editedQ3 call read: Track is in customer pre-production, PECVD progressing, still no production order named.
  4. 2026-11-10editedthe Q3 2026 10-Q, filed 6 November, was read and names no PECVD or Track production order
current state · 2026-11-06written 2026-08-31
The betAsymmetric
If it works
2.1×
from today's value, at the stated multiple
If it fails
keep 100%
of today's market value: the rest of the company, less its debt
How we value it
Method
Cash the business will produce, in three stages
Required return
8%
Long-run growth
4%
Moat
An average moat
BearBaseBull
Sales growth, years 1 to 312.3%, 13%, 8.6%24.7%, 26%, 17.2%30.9%, 32.5%, 21.5%
Normal operating margin12.9%16.1%17.7%
Return on new capital after year ten8%12%15%
Value a share$23.06$50.85$75.19
Price
$44.00
Priced on
16 Nov
Price as a share of the base value
87%
Starting growth the price pays for
20.1%
Yearly return the price offers on the base case
8.4%
Risk check: valued at 10%, the rate for a cyclical or indebted business
$26.63

Where each figure comes from

FigureSourceWhere exactly
Sales, the last twelve monthsFiled reportQuarterly report (10-Q) for the period to 30 Sep 2026, filed 6 Nov 2026; the four quarters to that date.
Operating margin todayFiled reportQuarterly report (10-Q) for the period to 30 Sep 2026, filed 6 Nov 2026; the four quarters to that date.
Tax rateFiled reportQuarterly report (10-Q) for the period to 30 Sep 2026, filed 6 Nov 2026; the four quarters to that date.
Sales per dollar of new capitalFiled reportAnnual report (10-K) for the period to 31 Dec 2025, filed 2 Mar 2026: the year's sales over its operating capital.
SharesFiled reportQuarterly report (10-Q) for the period to 30 Sep 2026, filed 6 Nov 2026; the diluted share count.
Cash and investmentsFiled reportQuarterly report (10-Q) for the period to 30 Sep 2026, filed 6 Nov 2026; the balance sheet on that date.
DebtFiled reportQuarterly report (10-Q) for the period to 30 Sep 2026, filed 6 Nov 2026; the balance sheet on that date.
Sales growth, years 1 to 3Analysts' forecastsFMP's consensus for the years to 31 Dec 2026, 31 Dec 2027 and 31 Dec 2028, as it stood when the value was struck on 17 Nov 2026: the average of 4 to 7 analysts' revenue estimates, 24.7%, 26%, 17.2%. FMP publishes how many analysts, not who they are.
Normal operating marginAnalysts' forecastsFMP's consensus operating margin for the year to 31 Dec 2028, the average of 6 analysts' estimates, 22.1%, less stock pay of 2.6% of sales and less the 4.1% the analysts add back on their adjusted basis: 15.5%, which the base case takes as 16.1%. FMP publishes how many analysts, not who they are.
Return on new capital after year tenOur method's ruleSet by our reading of the moat: the 8% rate with none, 12% with an average one, 15% with a strong one; the bear case earns the rate.
The bear and bull casesOur method's ruleOur method's spread: the bear case takes half the growth and a fifth off the margin, the bull a quarter more growth and a tenth more margin.
PriceMarket priceFMP's closing price on 16 Nov 2026.
Minority interestFiled reportQuarterly report (10-Q) for the period to 30 Sep 2026, filed 6 Nov 2026; the balance sheet on that date.

What each case rests on

Bear caseGrowth runs at half the analysts' path, 12%, 13% and 9%, the margin settles a fifth lower at 12.9%, and new capital earns only the 8% rate: the downturn test.

Base caseRevenue grows 25%, 26% and 17% over three years, the analysts' path (C59), then fades toward 4%, closing 30% of the gap each year; the margin moves to 16.1%, the analysts' year-three figure after stock pay and on the filed basis (4.2% less).

Bull caseGrowth runs a quarter above the analysts' path, 31%, 32% and 22%, the margin reaches 17.7%, and new capital earns 15%.

What moves the base value

LowerHigher
Growth in years 1 to 3, a quarter lower or higher$45.14$57.66
The normal margin, 15% lower or higher$39.74$61.95
Capital per dollar of growth, a quarter more or less$41.29$56.58
Return on new capital after year ten, at the rate or one step up$35.36$57.04
The rate, a point higher or lower$36.18$75.77
Long-run growth a point lower$44.08-

Value a share as growth and margin change

Normal margin ↓ · growth →50%75%100%125%150%
12.9%$30.68$33.10$36.04$39.59$43.83
14.5%$35.54$39.12$43.44$48.62$54.79
16.1%$40.40$45.14$50.85$57.66$65.75
17.7%$45.26$51.16$58.25$66.69$76.70
19.3%$50.12$57.19$65.65$75.73$87.66

Growth is shown as a share of the base case's. Green: the price is at or under 80% of that value. Red: at or over 120%.

How we read the multiple

Buyers pay about 13 times last year's operating profit for the whole company, debt included. Lam and Applied cost about 30 times. That makes sense only if sales keep growing and the gap to those two stays wide.

ACM grows second fastest of the three, is dearer than its own past on earnings but cheaper on cash profit, and earns the lowest return on the money invested in it.

Against its own history. Dearer than its own recent years on earnings, cheaper on cash profit. The business is bigger and faster growing, but cash has not followed profit.

The evidence under this - 3 claims
C40estimatemedium confidence
At the 4 November 2026 close, ACM's 12.9x EV/EBIT, down from 29.1x on 31 August and 19.1x on 22 October and 43% of the two-peer median of 29.75x, prices continued growth with less to spare: the discount to Lam Research and Applied Materials is wider than it was. C24 (ACM's own valuation history), C25 (the two-peer filed-cohort discount) and C03 (FY2026 guidance of 38%-42% growth) read together against the EV/EBIT frame.
derivedC24 (ACM's own valuation history), C25 (the two-peer filed-cohort discount) and C03 (FY2026 guidance of 25%-30% growth) read together against the EV/EBIT frame.
against this

A skeptic could read the same discount as the market correctly pricing structurally lower returns on capital (ROIC 4.4% vs a 23.5%-40.8% peer range, C25) rather than as a temporary gap that closes as growth continues.

  1. 2026-10-23editedre-struck at the 22 October close: 29.1x EV/EBIT to 19.1x, with the cohort median 42.1x to 30.65x; the reading moves from 'a narrowing discount' to a wider one, with the business evidence unchanged
  2. 2026-11-05editedre-struck at the 4 November close
current state · 2026-11-04written 2026-08-31
C24facthigh confidence
At the 4 November 2026 close of $44.43 ACM trades at a TTM P/E of 25.98x and EV/EBITDA of 8.01x, against prior-six-fiscal-year medians of 20.99x and 10.83x: the P/E is about 24% above its own median and the EV/EBITDA 26% below it. TTM ROIC is 5.3% versus a prior median of 6.3%.
  1. 2026-10-23editedre-struck at the 22 October close (49.12) from the 31 August close (72.82): P/E 32.25x to 22.47x and EV/EBITDA 14.83x to 9.92x, so ACM no longer trades above both of its own medians
  2. 2026-11-05editedre-struck at the 4 November close from a new pack
current state · 2026-11-04written 2026-08-31
C25facthigh confidence
Against the two listed, filing-confirmed competitors (Lam Research, Applied Materials), ACM trades at a discount on every cohort multiple at the 4 November 2026 close - EV/EBIT 12.9x vs a 29.75x median, EV/Sales 1.9x vs 10.0x, P/E 26.0x vs 32.25x - while its TTM revenue growth (29.1%) is the second highest of the three, behind Lam's 33.4%, and its operating margin (14.5%) and ROIC (5.3%) are the lowest.
  1. 2026-10-23editedre-struck at the 22 October close from 31 August: ACM's EV/EBIT 29.1x to 19.1x against a peer median of 42.1x to 30.65x; Lam's refreshed growth (33.4%) now exceeds ACM's 27.3%, so ACM is second fastest, not fastest
  2. 2026-11-05editedre-struck at the 4 November close from a new pack; the sentence on the group re-rating since 31 August dropped because the refreshed cohort carries no comparable history
current state · 2026-11-04written 2026-08-31
Priced against its rivals

The competitors its own annual report names, each confirmed against the rival's filing. Measured on company value for each $1 of operating profit, cheapest first:

TickerCompanycompany value for each $1 of operating profit
ACMRACM Research12.9×
LRCXLam Research28.3×
AMATApplied Materials31.2×

The middle of the other 2 is 29.8. ACM Research, Inc. is cheapest of 3.

Rivals' figures come from a data provider, so read the spread of the group rather than any single pair.

Cheaper than both listed rivals its own filing names, on every measure. The position is the company's own, and the risks below are what it pays for.

Private or foreign rivals that cannot be priced: Tokyo Electron Ltd., SCREEN Holdings Co., Ltd., NAURA Technology Group Co., Ltd., SEMES Co. Ltd., Kokusai Semiconductor Equipment Corporation, Suzhou Jingtuo Semiconductor Technology Co., Ltd.

The bet: what it pays if it works

This bet is on one business only: PECVD and Track, two new kinds of chip-making tool that customers are still testing. Everything else ACM sells is counted separately, at the company's own price for its sales, and if it meets this year's guidance it covers today's price on its own.

So today's price asks nothing of the new tools. But even a first foothold in their market adds little to the company's value, which makes it an expensive bet; if neither tool ever wins an order, little is lost.

PECVD and Track platforms revenue in two to three yearsPoints of that market neededAt the stated multiple
$83.00M (the big win)about 1 at 100% kept2.1×
$360.00M (market forecast)about 4 at 100% kept2.5×
$415.00Mabout 5 at 100% kept2.6×

SEMI's path carries PECVD and Track near $12 billion by 2029, about 30% in China; a 10% share of China, below Piotech's in PECVD, is about $360 million of revenue. On that forecast, $360.00M pays 2.5× from today's value: a Fair bet on the market case. PECVD and Track platforms would be worth about $1.40B, and the price pays nothing for it.

To pay 2× (a Fair bet) it would need about $11.02M of PECVD and Track platforms revenue (about 0 points of that market); to pay 5× (a Cheap bet), about $1.92B of PECVD and Track platforms revenue (about 23 points of that market), at the same multiple.

Each row is PECVD and Track platforms alone, plus the rest of the company (Cleaning, ECP plating, furnace and advanced-packaging tools) counted at about $4.91B.

The steps it has to take

  • Done PECVD and Track evaluation tools placed with customers
  • Slipped Production qualification of PECVD or Track due 2026-12
  • Not started A first disclosed production order for PECVD or Track due 2026-12
  • Not started Repeat production orders from the qualifying customer, the path most of ACM's tools follow due 2027-12
  • Not started PECVD and Track revenue near one point of their combined market, about $83 million a year due 2028-12
The detail behind the label
Rating
Fair
the big win's payoff against the 2× and 5× lines
Cheap bet at about
≈ $27.75
44% below the price (close, )
The option
free
what PECVD and Track platforms is worth if it works, and the price pays nothing for it
Market case
2.5×
a fair bet if the market forecast holds
The evidence under this - 4 claims
C23facthigh confidence
As of the Q3 2026 release on 5 November, ACM's PECVD and Track platforms are not reported as separate product lines and neither the release nor the Q3 10-Q, filed 6 November, names a production order for either; as of the Q2 2026 call both were in customer evaluation with production qualification anticipated by year-end 2026. On the Q3 call the chief executive said the Track system has started customer pre-production alongside a scanner and PECVD is making progress, but no production order was named.
against this

A related new platform, horizontal panel-level plating, already booked its first production order in Q2 2026 (C35), which management points to as evidence the evaluation-to-production path is real rather than a standing promise.

  1. 2026-10-23editedACM's own notice of 19 October sets the third-quarter results for 5 November, not the 4 November a vendor estimated; the refresh date moves with it
  2. 2026-11-05editedQ3 release names no PECVD or Track production order
  3. 2026-11-05editedQ3 call read: Track is in customer pre-production, PECVD progressing, still no production order named.
  4. 2026-11-10editedthe Q3 2026 10-Q, filed 6 November, was read and names no PECVD or Track production order
current state · 2026-11-06written 2026-08-31
C21management claimmedium confidence
ACM estimates, from third-party reports and customer data, that its current products address about $7.3B of wafer cleaning, $5.3B of PECVD, $3.0B of Track, $2.6B of furnace and $1.5B of ECP within the global WFE market.
against this

The by-product-line SAM figures are described as based on 'third-party reports and customer information' without naming which third parties beyond the general Frost & Sullivan citation used elsewhere, so the individual product-line splits cannot be independently checked against a named external source.

current state · 2026-03-02written 2026-08-31
C03facthigh confidence
Q2 2026 revenue was $292.9 million, up 36.0% year over year; FY2026 revenue guidance was raised to $1.125-1.175 billion in August and to $1.24-1.28 billion (38%-42% growth) on 5 November, which implies Q4 revenue of $348M to $388M.
  1. 2026-10-23editedACM's own notice of 19 October sets the third-quarter results for 5 November, not the 4 November a vendor estimated; the refresh date moves with it
  2. 2026-11-05editedQ3 release raised the 2026 revenue guide a second time
forwardwritten 2026-08-31
C25facthigh confidence
Against the two listed, filing-confirmed competitors (Lam Research, Applied Materials), ACM trades at a discount on every cohort multiple at the 4 November 2026 close - EV/EBIT 12.9x vs a 29.75x median, EV/Sales 1.9x vs 10.0x, P/E 26.0x vs 32.25x - while its TTM revenue growth (29.1%) is the second highest of the three, behind Lam's 33.4%, and its operating margin (14.5%) and ROIC (5.3%) are the lowest.
  1. 2026-10-23editedre-struck at the 22 October close from 31 August: ACM's EV/EBIT 29.1x to 19.1x against a peer median of 42.1x to 30.65x; Lam's refreshed growth (33.4%) now exceeds ACM's 27.3%, so ACM is second fastest, not fastest
  2. 2026-11-05editedre-struck at the 4 November close from a new pack; the sentence on the group re-rating since 31 August dropped because the refreshed cohort carries no comparable history
current state · 2026-11-04written 2026-08-31

Where we disagree with the market

The market believes

A Chinese equipment winner riding AI and the push for home-grown tools, worth buying on the dip: 8 of 10 analysts say buy.

We believe

The growth is real, but it sits in unproven tool lines and in the one market forecast to shrink.

The market sees three raised forecasts and earnings beats in 6 of the last 8 quarters. But the reported figure is flattered or hurt by paper gains and losses on investments, and the cash statement and the shrinking stake in the Chinese arm sit far from the headline.

If the new lines win production orders and cash turns positive, management's confidence was earned and we were too cautious. Cleaning growing again removes one of our doubts, not the others.

What analysts say, and the evidence
Analysts positive
90%
of 10, 1 Nov
Four months earlier
88%
of 8, 1 Jul
The evidence under this - 8 claims
C28facthigh confidence
Sell-side consensus is 8 buy, 2 hold, 0 sell.
current state · 2026-08-31written 2026-08-31
C36facthigh confidence
ACM beat consensus EPS in 6 of its last 8 reported quarters; the two misses were both fourth-quarter prints (2025-02-26 and 2026-02-26), where no discrete filed GAAP EPS exists for comparison.
historical · trailing 8 quarters through Q2 2026written 2026-08-31
C03facthigh confidence
Q2 2026 revenue was $292.9 million, up 36.0% year over year; FY2026 revenue guidance was raised to $1.125-1.175 billion in August and to $1.24-1.28 billion (38%-42% growth) on 5 November, which implies Q4 revenue of $348M to $388M.
  1. 2026-10-23editedACM's own notice of 19 October sets the third-quarter results for 5 November, not the 4 November a vendor estimated; the refresh date moves with it
  2. 2026-11-05editedQ3 release raised the 2026 revenue guide a second time
forwardwritten 2026-08-31
C06facthigh confidence
Q2 2026 GAAP diluted EPS of $1.23 exceeded non-GAAP EPS of $0.61 because of a $69.6 million unrealized mark-to-market gain on ACM Shanghai's short-term investments (versus $2.7 million a year earlier); non-GAAP also excludes stock-based compensation.
historical · Q2 2026written 2026-08-31
C07facthigh confidence
Operating cash flow was negative in six of the last seven quarters (FY2025 -$10.3M; Q1 2026 -$29.5M; Q2 2026 -$6.4M; Q3 2026 -$70.4M, the nine months' filed -$106.3M less the first half), driven in FY2025 by a $108.2M inventory build and $116.1M receivables growth and in 2026 by a $135.2M nine-month inventory build; free cash flow was -$51.7M in Q1 2026, -$71.5M in Q2 2026 and -$100.3M in Q3 2026 (nine months -$223.5M filed).
against this

The cash consumption is working-capital growth (inventory and receivables) behind a growing, mostly-GAAP-profitable business, not an operating loss, and the balance sheet holds $1.0 billion of net cash against it (C34) - a multi-year buffer at the current burn rate.

  1. 2026-11-10editedthe Q3 2026 10-Q, filed 6 November, was read: operating cash flow was negative again in Q3, by $70.4M, and free cash flow was -$100.3M
historical · FY2025 through Q2 2026written 2026-08-31
C08facthigh confidence
ACM Research holds a direct 72.8% ownership interest in ACM Shanghai, its principal operating subsidiary listed on Shanghai's STAR Market (688082), down from 74.6% at 31 December 2025 and 73.2% at 30 June 2026: ACM sold ACM Shanghai shares for $110.2M gross in the nine months, and ACM Shanghai employees' option exercises diluted it further; the September 2025 private offering had raised about $623 million.
against this

74.6% is still a clear controlling, consolidating majority stake, and ACM Shanghai paid a $36.8 million dividend up to ACM Research and minority holders in the same September 2025 window (C33), so capital has flowed back as well as out.

  1. 2026-11-10editedthe Q3 2026 10-Q, filed 6 November, was read: the stake is 72.8% at 30 September, down from 74.6% at the year end
current state · 2026-09-30written 2026-08-31
C23facthigh confidence
As of the Q3 2026 release on 5 November, ACM's PECVD and Track platforms are not reported as separate product lines and neither the release nor the Q3 10-Q, filed 6 November, names a production order for either; as of the Q2 2026 call both were in customer evaluation with production qualification anticipated by year-end 2026. On the Q3 call the chief executive said the Track system has started customer pre-production alongside a scanner and PECVD is making progress, but no production order was named.
against this

A related new platform, horizontal panel-level plating, already booked its first production order in Q2 2026 (C35), which management points to as evidence the evaluation-to-production path is real rather than a standing promise.

  1. 2026-10-23editedACM's own notice of 19 October sets the third-quarter results for 5 November, not the 4 November a vendor estimated; the refresh date moves with it
  2. 2026-11-05editedQ3 release names no PECVD or Track production order
  3. 2026-11-05editedQ3 call read: Track is in customer pre-production, PECVD progressing, still no production order named.
  4. 2026-11-10editedthe Q3 2026 10-Q, filed 6 November, was read and names no PECVD or Track production order
current state · 2026-11-06written 2026-08-31
C05facthigh confidence
In Q2 2026, cleaning revenue fell 14% year over year to $133 million (45% of revenue), while ECP/furnace/other grew 168% and advanced packaging (ex-ECP) grew 153%.
against this

Management said the cleaning decline reflects a product-cycle transition, not lost share: SPM (about a third of the cleaning market by ACM's own estimate) had 'very little revenue today' but a handful of tools shipped in H1 2026 with more than 20 guided for H2, so the segment total is depressed by a new-product ramp rather than only by losses at existing accounts.

historical · Q2 2026written 2026-08-31
06

What could go wrong, and how we would know

The risks

  • Both operating arms blacklisted. Since December 2024 nobody anywhere may supply ACM Shanghai or ACM Korea with controlled American technology without a US licence.
  • One country, forecast to shrink. Substantially all sales have gone to mainland China, where equipment spending is forecast to fall 9.9% in 2026.
  • A few big customers. Four customers were 52% of 2025 sales and 62% of what customers owed at the year end.
  • Profit that is not cash. Operations consumed cash in five of the last six quarters, as unsold inventory and unpaid customer bills piled up.
  • Insiders selling. Insiders made 69 open-market sales and no purchases over the last year.
The evidence under this - 6 claims
C09facthigh confidence
ACM Shanghai and ACM Korea were added to the U.S. BIS Entity List effective December 2, 2024, barring any party worldwide from supplying them U.S.-export-controlled hardware, software or technology without authorization.
against this

A filed ACM Shanghai investor-relations record states all non-standard components are now fully localized and that progress has been made on localizing certain critical standard components (C42) - more concrete, filed detail than the general assurance management gave on the Q2 2026 call (C29).

current state · 2026-03-02written 2026-08-31
C11facthigh confidence
Substantially all of ACM's historical semiconductor-equipment sales have been to customers in mainland China; the company is expanding direct sales in North America, Europe and Southeast Asia.
current state · 2026-03-02written 2026-08-31
C20factmedium confidence
ACM's own 10-K cites Gartner estimating global WFE grew to $138.5 billion in 2026 (up 11.8%) while mainland-China WFE is estimated to decline 9.9%, from $39.3 billion in 2025 to $35.4 billion in 2026.
forwardwritten 2026-08-31
C10facthigh confidence
Four customers accounted for 52.2% of FY2025 revenue (17%, 14%, 12%, 10% individually) and four customers were 62% of accounts receivable at year-end 2025.
historical · FY2025written 2026-08-31
C07facthigh confidence
Operating cash flow was negative in six of the last seven quarters (FY2025 -$10.3M; Q1 2026 -$29.5M; Q2 2026 -$6.4M; Q3 2026 -$70.4M, the nine months' filed -$106.3M less the first half), driven in FY2025 by a $108.2M inventory build and $116.1M receivables growth and in 2026 by a $135.2M nine-month inventory build; free cash flow was -$51.7M in Q1 2026, -$71.5M in Q2 2026 and -$100.3M in Q3 2026 (nine months -$223.5M filed).
against this

The cash consumption is working-capital growth (inventory and receivables) behind a growing, mostly-GAAP-profitable business, not an operating loss, and the balance sheet holds $1.0 billion of net cash against it (C34) - a multi-year buffer at the current burn rate.

  1. 2026-11-10editedthe Q3 2026 10-Q, filed 6 November, was read: operating cash flow was negative again in Q3, by $70.4M, and free cash flow was -$100.3M
historical · FY2025 through Q2 2026written 2026-08-31
C27facthigh confidence
Over the trailing 365 days, insiders made zero open-market purchases and 69 open-market sales; CFO Mark McKechnie sold about 55,000 shares across three trades on 2026-08-20 in the $76-78 range, and directors/officers sold smaller amounts on 2026-06-05 and 2026-08-18.
against this

The filings classify these sales as tied to standing compensation plans (officer 'See Remarks' filings), not as a single discretionary decision to exit; the pattern is still a real absence of open-market buying at any point in the trailing year.

current state · 2026-08-20written 2026-08-31
What we still do not know
  • How far a planned Hong Kong listing of the Chinese subsidiary, now approved by its shareholders, would shrink ACM Research's 72.8% stake.
  • Whether swapping blacklisted American parts for local ones works, beyond the company saying so.
  • How much more outside money the Chinese arm will raise, and at whose expense.
The evidence under this - 4 claims
C08facthigh confidence
ACM Research holds a direct 72.8% ownership interest in ACM Shanghai, its principal operating subsidiary listed on Shanghai's STAR Market (688082), down from 74.6% at 31 December 2025 and 73.2% at 30 June 2026: ACM sold ACM Shanghai shares for $110.2M gross in the nine months, and ACM Shanghai employees' option exercises diluted it further; the September 2025 private offering had raised about $623 million.
against this

74.6% is still a clear controlling, consolidating majority stake, and ACM Shanghai paid a $36.8 million dividend up to ACM Research and minority holders in the same September 2025 window (C33), so capital has flowed back as well as out.

  1. 2026-11-10editedthe Q3 2026 10-Q, filed 6 November, was read: the stake is 72.8% at 30 September, down from 74.6% at the year end
current state · 2026-09-30written 2026-08-31
C37facthigh confidence
On May 29, 2026, ACM Shanghai's board approved a plan to issue new H Shares and list on the Main Board of the Hong Kong Stock Exchange, for up to 7% of total post-offering share capital plus a 15% over-allotment option, with proceeds earmarked for R&D, global market expansion, working capital and bank-loan repayment; by the Q3 2026 10-Q its shareholders had approved it too, and it remains subject to market conditions and to filings and approvals including the China Securities Regulatory Commission's and the Hong Kong exchange's.
against this

Management said on the Q2 2026 call it 'cannot comment too much on the Hong Kong listing at this time' beyond a previously announced timeline, and the plan still requires shareholder approval, so timing and even completion are not certain.

  1. 2026-10-23editedACM's own notice of 19 October sets the third-quarter results for 5 November, not the 4 November a vendor estimated; the refresh date moves with it
  2. 2026-11-10editedthe Q3 2026 10-Q, filed 6 November, was read: ACM Shanghai's shareholders have approved the H-share plan, which still waits on regulators and the market
forwardwritten 2026-08-31
C42factmedium confidence
The same filed record states all non-standard components are now fully localized and that ACM Shanghai has made progress localizing certain critical standard components (magnetic-drive pumps, heaters, filters), which it cites as mitigating supply risk from the BIS Entity List restriction.
current state · 2026-06-16written 2026-08-31
C32inferencemedium confidence
Because ACM Shanghai has repeatedly raised its own outside capital (the September 2025 private offering cut ACM Research's stake to 74.6%), further ACM Shanghai capital raises would keep diluting ACM Research shareholders' claim on ACM Shanghai's earnings even as consolidated revenue keeps growing.
derivedC08 (ownership fell after the September 2025 raise) combined with the pattern of ACM Shanghai independently accessing China's capital markets through its own STAR listing and a follow-on private placement, while ACM Research separately raised its own equity in May 2026 (C15) - a subsidiary with its own listing and its own capital-raising history is structurally likely to raise again as it funds Lingang and other expansion.
against this

ACM Shanghai also paid a $36.8 million dividend up to ACM Research and NCI holders in September 2025 (C33), so capital has flowed back as well as out, and 74.6% remains a clear majority stake with consolidation and control intact.

forwardwritten 2026-08-31

What would change our view

  1. Neutral→AttractiveThe price falls 20% under fair value

    It needs:

    • ○The share price falls to about $40.68, 80% of what we think the business is worth, so it is cheap enough.about ≈$40.62 today, 19% below the last close
  2. Neutral→UnattractiveThe price runs 20% above fair value

    It needs:

    • ○The share price rises to about $61.02, 20% above what we think the business is worth.about ≈$61.37 today, 23% above the last close
  3. Neutral→UnattractiveThe China risks land

    It needs any of:

    • ○A further American export restriction limits what the Chinese subsidiary can buy or ship.watched as it happens
    • ○The Chinese subsidiary lists in Hong Kong, further shrinking ACM Research's share of its own operating business.watched as it happens
We would also be wrong if
  • Operations keep consuming cash for two more quarters despite the reported profit.

What is coming

  • December 2026 PECVD and Track production qualification: Whether either platform leaves customer evaluation by year-end as guided; another slip would test the execution record and the potential axis.
Every dated event ahead
  • December 2026 PECVD and Track production qualification: Whether either platform leaves customer evaluation by year-end as guided; another slip would test the execution record and the potential axis.
  • February 2027 Q4 and FY2026 results and the FY2026 10-K: Full-year revenue against the $1.125-1.175B guide, cash flow after the inventory build, the ACM Shanghai stake, and whether high-temperature SPM passed 20 systems.
  • March 2027 First volume-production panel-level plating system delivered: Whether the panel-level plating line turns from one order into a shipped production tool, the first test of the advanced-packaging prize outside cleaning.
Since we wrote this
Written
31 Aug
Price the thesis read
$44.43
4 Nov
Latest close
$49.88
close, · +12.3% since
  • 17 NovPrice moveShares fell 12%; our value now counts the Chinese arm's outside ownersThe price crossed our buy line, but that line ignored the 27.2% of ACM Shanghai others own. Counting it, the value is about $50.85 and $44.00 is 87% of it, so Neutral held.
  • 13 NovBet moveBet re-struck: Safe, little upside to AsymmetricRe-priced at the 12 November close; the rating moved from Expensive bet to Fair bet.
  • 12 NovBet moveBet re-struck: Asymmetric to Safe, little upsideRe-priced at the 11 November close; the rating moved from Fair bet to Expensive bet.
  • 10 NovPrice moveThe price rose through our 80% line; view moved to NeutralAn 11% one-day rise to $49.75 left the shares at 86% of our value of $57.65, inside the 20% margin of safety, so the view moved from Attractive to Neutral.
  • 10 NovEarningsQuarterly filing: cash used again, no new-tool orderThe 10-Q shows $70.4M of operating cash used in the quarter and no PECVD or Track order, and the stake fell to 72.8%. The view holds at Neutral.
  • 9 NovThesis reviewAttractive: priced at 77% of a value near $57.65Re-valued in three stages at an 8% return, the method now drawn on every thesis: the price sits past the 20% margin of safety.
  • 5 NovEarningsSales up 37%, cleaning grew again; no new-line order yetThe cleaning rebound came and the sales forecast rose. A first PECVD or Track order and cash from operations are not in the release, so Neutral holds.
  • 2 NovBet moveBet re-struck: Safe, little upside to AsymmetricRe-priced at the 30 October close; the rating moved from Expensive bet to Fair bet.
  • 28 OctNewsACMR pre-announces Q3 revenue up 34-36%, with shipments growing slower than revenue. View heldACM Research's preliminary third-quarter revenue is $360-365 million, up 34-36%; shipments $335-340 million.
  • 23 OctPrice moveShares fell a third; ACM now level with its own historyValuation claims were re-struck at the 22 October close. The discount to Lam and Applied widened as the whole group fell, the business evidence did not move, and the view held.
  • 5 OctThesis reviewThe bet now names what it ridesThe owner asked that every bet name the macro trend behind it, after BWXT's bet was missing its chief executive's case for nuclear over gas.
  • 4 OctThesis reviewOwner's checklist: revenue streams, cost of growth, management, catalystsThe owner's checklist found the method silent on who runs the company, what growth costs, where the money comes from and what is dated ahead; this pass fills those four blocks from the proxy and filings.
  • 1 OctNewsShanghai backlog up 88.2%; view heldThe filed backlog of RMB 17.1 billion agrees with the order growth management cited. It does not say whether cleaning revenue rebounds or new platforms win orders, so the November print stays the test.
  • 31 AugThesis writtenNeutral, medium convictionWritten after June-quarter results raised the full-year forecast while the core cleaning line shrank 14% and operations used cash again.

Also checked 2 times with nothing new to act on.

Sources 27

Where this came from

Sources - 27

Every claim above cites one of these, or states the reasoning that derived it. The quote is frozen at the date it was read: a link can rot, and an agent fetch returns a reading of a page rather than the page. Backs counts the whole claim ledger, so it can name a claim this page does not surface.

  1. S01primarycompany filing2026-03-02
    business description, competition, risk factors (export controls, customer concentration), ownership structure, dual-class structure, cash-flow drivers, customer/AR concentration
    backsC01C02C04C07C08C09C10C11C14C16C18C20C21C24C25C30C31C33C54C55
  2. S02primarycompany filing2026-08-07
    Q2 2026 GAAP/non-GAAP financials and reconciliation, guidance, cash and debt position
    backsC03C05C06C24C34C36
  3. S03primarytranscript2026-08-07
    Q2 2026 earnings call transcript (prepared remarks and Q&A)
    management commentary and figures with no filed home (SAM, long-term target, order growth, product-line color); analyst Q&A on China exposure, component supply, Hong Kong listing
    For the first half of 2026, orders increased 105% year-over-year. This is a mix across all product categories with a heavier emphasis on some of our new products.
    backsC05C12C13C18C22C23C29C34C35C45C50
  4. S04primarycompany filing2026-05-12
    terms of the May 2026 $150 million equity raise
    backsC15
  5. S05primaryvendor data2026-08-31
    Research pack - market and vendor-fundamentals tiers (FMP, IBKR, Form 4 filings)
    price/valuation history, peer_valuation cohort multiples, earnings history and EPS-beat record, insider transactions, analyst consensus
    backsC02C07C24C25C27C28C36
  6. S06primarygovernment data2026-08-14
    FINRA consolidated short interest
    short interest percent of float and days-to-cover, settled 2026-08-14
    backsC26
  7. S07primarycompany filing2026-02-26
    original FY2026 guidance ($1.08-1.175bn, 21%-30% growth) later raised in Q2; the February 6, 2026 sale of about 1.3% of ACM Research's ACM Shanghai stake for ~$111 million; year-end 2025 net cash
    backsC38
  8. S08primarycompany filing2026-08-07
    outside confirmation that 'clean' is a named Lam market, and that installed-base/repeat-order dynamics are a named competitive mechanism industry-wide
    backsC17
  9. S09primarycompany filing2025-12-12
    Semiconductor Systems segment description (deposition as one of several named process steps) used for the competitor-cohort perimeter judgement
    read, but no claim rests on it
  10. S10primaryindustry data2025-12-16
    SEMI, 'Global Semiconductor Equipment Sales Projected to Reach a Record of $156 Billion in 2027' (press release) SEMI
    an independent, non-company-selected global WFE and mainland-China spending forecast to check against the Gartner figures ACM's own 10-K cites
    WFE segment sales are projected to expand 9.0% in 2026 and 7.3% in 2027 ... China is projected to maintain the leading position over the forecast period ... sales gradually decline from 2026
    backsC19
  11. S11primarycompany filing2026-05-29
    terms of ACM Shanghai's proposed Hong Kong H-share listing: up to 7% of post-offering share capital plus a 15% over-allotment option, subject to shareholder approval, and the intended use of proceeds
    backsC37
  12. S12secondarynews2026-04-20
    DigiTimes, 'Naura revenue climbs on China chip tool demand, margins tighten amid rising costs and competition'
    an outside, non-ACM account of NAURA's growth and the domestic-substitution dynamic named as a threat in machine.threat
    China semiconductor equipment maker Naura Technology delivered strong 2025 revenue growth on rising chip tool demand and domestic substitution, but weaker margins and intensifying competition signal a tougher next phase.
    backsC39
  13. S13primarycompany filing2026-06-22
    a filed (STAR Market Reg-FD) Q&A record with a different $4bn target split than the Q2 call, component-localization detail, Q1 2026 order growth (65% YoY, a filed figure distinct from the 105% H1 figure), and Lingang Plant A/B capacity detail
    backsC41C42
  14. S14primarycompany filing2026-09-30
    ACM Shanghai total backlog RMB 17.1bn (USD 2.5bn) at 2026-09-29, +88.2% year on year, with the company's own caveats on the measure; and the dates of the nine-month results (28 October) and Q3 call (early November)
    backsC43
  15. S15primaryindustry data2026-04-01
    the industry body's fab-equipment spending path to 2029, the growth rate the PECVD and Track market is carried forward on; read through ir_fetch
    Worldwide 300mm fab equipment spending is expected to increase 18% to $133 billion in 2026 and 14% to $151 billion in 2027, SEMI reported today in its latest 300mm Fab Outlook. ... Looking further out, the report projects investment will continue to increase 3% to $155 billion in 2028 and another 11% to $172 billion in 2029, respectively.
    backsC44
  16. S16primarytranscript2026-04-30
    the Track incumbent's own account: 91% world coater/developer share in CY2025 (Gartner), coater/developer 28% of FY2026 new-equipment sales of 1,775.4 billion yen, China 34.1% of FY2026 sales and 26.8% in Q4, a CY2026-27 WFE outlook of $150-170 billion a year; read through the ir_fetch client and pdftotext
    In the coater/developer business, in particular, our share in the global market exceeds 90%. ... On the full-year basis in the fiscal year ended March 2026, proportion of sales in China was 34.1%.
    backsC46
  17. S17primarycompany filing2026-04-28
    China's domestic PECVD leader's 2025 PECVD revenue and its SEMI-based sizing of thin-film and PECVD markets, globally and in mainland China; read through the ir_fetch client and pdftotext
    公司 PECVD 系列设备实现销售收入约 51.42 亿元,同比增长 75.27% ... 根据 SEMI 历史统计,PECVD 是薄膜设备中占比最高的设备类型,约占整体薄膜沉积设备市场的 33%
    backsC47
  18. S18primarycompany filing2026-04-18
    China's domestic Track leader's 2025 revenue (RMB 1.948 billion, +11.11%) and its statement that front-end Track localisation in China remains low; read through the ir_fetch client and pdftotext
    全球前道涂胶显影设备市场长期被海外厂商高度垄断,目前国产化率仍然较低。
    backsC48
  19. S19primarycompany filing2026-04-27
    beneficial ownership and voting power as of April 13, 2026, the executive officers and their start dates, the CD&A's discretionary bonus and stock-option design, the 2025 bonuses
    backsC51C52C53
  20. S20primarycompany filing2023-03-02
    the FY2021 and FY2022 income statement and capital spending, read through the frozen numbers card (content/ACMR/financials.json)
    backsC54C55
  21. S21primarycompany filing2026-08-07
    the first-half 2026 cost lines behind the trailing year, the financing cash flows (ACM Shanghai stake sale, the May 2026 share issue) and the June 2026 Shanghai office purchase and its Bank of China loan
    backsC54C55
  22. S22primarycompany filing2026-08-27
    the delivery dates for the first volume-production panel-level plating system and the panel evaluation system, the high-temperature SPM shipment target for 2026, and the September 30 backlog disclosure
    backsC56
  23. S23primarycompany filing2026-11-05
    Q3 revenue, margins, operating income and earnings per share, revenue by product category, shipments, the raised 2026 revenue guide, the balance sheet at 30 September and the October announcements
    backsC03C13C23C34C57C58
  24. S24primarytranscript2026-11-05
    ACM Research Q3 2026 earnings call transcript (FMP), held November 5, 2026
    Track in customer pre-production, Q4 shipments expected higher, global customers 20 tools outside mainland China by year end, gross margin target 42%-48%, normal inventory provision, raw materials stocked with cash.
    Our Track system started getting to their pre-production together with scanner. All the PECVD made a progress too.
    backsC13C23
  25. S25primarycompany filing2026-11-09
    trailing revenue, operating profit, stock pay, tax, debt, cash and the diluted share count
    backsC60
  26. S26secondaryvendor data2026-11-09
    the analysts' average revenue and operating profit for the next three fiscal years, and the close
    backsC59C60
  27. S27primarycompany filing2026-11-06
    nine-month operating cash flow of -$106.3M and free cash flow of -$223.5M, the 72.8% stake in ACM Shanghai, shareholder approval of the H-share plan, the $22.1B addressed market, and no PECVD or Track production order
    backsC07C08C12C23C37
Rendered from content/ACMR/thesis.json · thesis reviewed 2026-11-17. This page explains a company; it does not say what to pay, when to buy or how much.